The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
HER2-positive breast cancer
Neo-adjuvant treatment
T-cells
Tumour infiltrating lymphocytes
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
16
05
2020
accepted:
22
04
2021
pubmed:
14
5
2021
medline:
24
6
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels with subsequent pCR, few have studied the impact of neoadjuvant therapy on the immune environment. We performed TIL analysis and T-cell analysis by IHC on the pretreatment and 'On-treatment' samples from patients recruited on the Phase-II TCHL (NCT01485926) clinical trial. Data were analysed using the Wilcoxon signed-rank test and the Spearman rank correlation. In our sample cohort (n = 66), patients who achieved a pCR at surgery, post-chemotherapy, had significantly higher counts of TILs (p = 0.05) but not SLs (p = 0.08) in their pre-treatment tumour samples. Patients who achieved a subsequent pCR after completing neo-adjuvant chemotherapy had significantly higher SLs (p = 9.09 × 10 The immune system may be 'primed' prior to neoadjuvant treatment in those patients who subsequently achieve a pCR. In those patients who achieve a pCR, their immune response may return to baseline after only 1 cycle of treatment. However, in those who did not achieve a pCR, neo-adjuvant treatment may stimulate lymphocyte influx into the tumour.
Sections du résumé
BACKGROUND
BACKGROUND
Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels with subsequent pCR, few have studied the impact of neoadjuvant therapy on the immune environment.
METHODS
METHODS
We performed TIL analysis and T-cell analysis by IHC on the pretreatment and 'On-treatment' samples from patients recruited on the Phase-II TCHL (NCT01485926) clinical trial. Data were analysed using the Wilcoxon signed-rank test and the Spearman rank correlation.
RESULTS
RESULTS
In our sample cohort (n = 66), patients who achieved a pCR at surgery, post-chemotherapy, had significantly higher counts of TILs (p = 0.05) but not SLs (p = 0.08) in their pre-treatment tumour samples. Patients who achieved a subsequent pCR after completing neo-adjuvant chemotherapy had significantly higher SLs (p = 9.09 × 10
CONCLUSIONS
CONCLUSIONS
The immune system may be 'primed' prior to neoadjuvant treatment in those patients who subsequently achieve a pCR. In those patients who achieve a pCR, their immune response may return to baseline after only 1 cycle of treatment. However, in those who did not achieve a pCR, neo-adjuvant treatment may stimulate lymphocyte influx into the tumour.
Identifiants
pubmed: 33983492
doi: 10.1007/s10549-021-06244-1
pii: 10.1007/s10549-021-06244-1
pmc: PMC8197702
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
635-645Subventions
Organisme : Irish Cancer Society
ID : CCRC13GAL
Références
J Cancer. 2017 Oct 17;8(18):3838-3848
pubmed: 29151971
Ann Oncol. 2012 Jul;23(7):1788-95
pubmed: 22056974
Breast Cancer Res Treat. 2018 Aug;171(1):1-9
pubmed: 29774470
Ann Oncol. 2018 Jan 1;29(1):170-177
pubmed: 29045543
Ann Oncol. 2017 Sep 1;28(9):2233-2240
pubmed: 28911063
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Lancet Oncol. 2014 Sep;15(10):1137-46
pubmed: 25130998
Clin Cancer Res. 2019 Aug 1;25(15):4644-4655
pubmed: 31061067
Annu Rev Immunol. 2003;21:107-37
pubmed: 12414720
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Immunity. 2011 Aug 26;35(2):161-8
pubmed: 21867926
Cancer Treat Rev. 2017 Jun;57:8-15
pubmed: 28525810
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
J Natl Cancer Inst. 2016 Jul 04;108(8):
pubmed: 27377904
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
Sci Rep. 2017 Dec 21;7(1):18027
pubmed: 29269742
Nat Commun. 2020 Nov 17;11(1):5824
pubmed: 33203854
Breast Cancer. 2018 May;25(3):268-274
pubmed: 29185202
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Genome Biol. 2016 Dec 1;17(1):249
pubmed: 27908289
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Natl Cancer Inst. 2016 Oct 13;109(1):
pubmed: 27737921
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Mol Med Rep. 2018 Nov;18(5):4247-4258
pubmed: 30221739
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
Target Oncol. 2018 Dec;13(6):757-767
pubmed: 30406444
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419